

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hans J. HANSEN et al. Confirmation No.:
Appl. No.: 09/382,186 Examiner: David A. Saunders
Filing Date: August 23, 1999 Art Unit: 1644
Title: USE OF BI-SPECIFIC ANTIBODIES FOR PRE-TARGETING DIAGNOSIS
AND THERAPY

Response To Notice Of Non-Compliant Amendment

Under 37 C.F.R. § 1.121

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450,
Alexandria, VA

Sir:

This is a response to the Notice of Non-Compliant Amendment mailed October 30, 2003 in the captioned application. Pursuant to 37 C.F.R. § 1.121 and 37 C.F.R. § 1.136(a), submitted herewith are extension fees as required. Although applicants believe that the amount of the attached check is correct, the Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 08-1641.

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

33. (Previously amended) A method of preparing a bi-specific Fab-scFv fusion protein having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and one or more conjugated therapeutic or diagnostic agents, or enzymes, comprising: